KR100873946B1 - Agents for improving wrinkles on skin comprising alpha-pinene as an active ingredient - Google Patents

Abstract

A composition for improving the skin wrinkle is provided to remove toxicity and side effect, thereby allowing the composition to be used safely for a long time. A composition for improving the skin wrinkle contains 0.0001-10.0 wt% of alpha-pinene as an effective ingredient. Preferably the composition for improving the skin wrinkle is a cosmetic composition, a pharmaceutical composition or a food composition.

Description

Agents for Improving Wrinkles on Skin Comprising Alpha-pinene as an Active Ingredient}

1 is a graph showing the effect of promoting collagen (type I collagen) biosynthesis by alpha-pinene. RA stands for retinoic acid. RA was treated in amounts of 1 μM and alpha-pinene in amounts of 1 μM, 10 μM and 50 μM.

2 is a graph showing the effect of inhibiting collagenase (MMP-1) activity by increasing the treatment concentration of alpha-pinene, the active ingredient of the present invention. MMP-1 and PMA represent type I collagenase and phorbol myristate acetate, respectively. PMA was treated in amounts of 200 nM and alpha-pinene in amounts of 1 μM, 10 μM and 50 μM.

The present invention relates to a composition for skin, and more particularly, it has excellent product stability and can be safely used without side effects on the skin, and has anti-wrinkle effect, anti-inflammatory effect, anti-obesity effect, hair loss prevention and hair growth effect. It relates to a composition for skin containing as an active ingredient.

Wrinkles are the result of aging of the skin, and aging skin is the aggregate of the natural changes associated with the process of aging. Skin aging is divided into two categories, physiological aging, which indicates a change in skin function, structure, or shape related to age, and photoaging by ultraviolet rays.

As the skin ages, the changes in the dermis appear remarkably, and dermis atrophy after 70 years is a representative aging phenomenon. Changes in the dermis are caused by changes in substances with large molecular weight in the extracellular matrix due to a decrease in the number of fibroblasts and their ability to synthesize. Specific changes include separation of collagen bundles, reduced point polysaccharide synthesis, decreased collagen and elastic fiber counts and diameters, grinding collagen and elastic fibers, and expansion of blood vessels. Generally, among the various factors such as skin moisture content, collagen content, and ability to immunize the external environment, the biggest influence on wrinkle formation is collagen, a collagen degrading enzyme that reduces collagen production and collagen content. It is the expression level and activity of genease. The effect of alpha-pinene on collagen and collagenase enzymes was not revealed, but this experiment showed that alpha-pinene increased collagen synthesis and inhibited collagenase enzyme.

 Hormonal imbalances are aggravating due to environmental pollution and automobile exhaust. As a result, the incidence of hair loss increases, the age of incidence decreases, and the immunity of the skin immune system is caused, resulting in various skin diseases such as atopy and psoriasis. In addition, the population suffering from obesity is rapidly increasing despite the age of children due to the changes in the diet of meat and meat.

Therefore, the development of materials that can effectively solve various phenomena, such as endogenous aging and wrinkles caused by ultraviolet rays, obesity, immune imbalance and hair loss, as well as aesthetic issues, are being studied in depth. Under these backgrounds, the present inventors searched for active substances in plant-derived compounds in order to find cosmetics having high safety and stability and excellent skin-related efficacy, and alpha-pinene has various effects including wrinkles and anti-inflammatory, At the same time, it was confirmed that the safety and stability is excellent.

Throughout this specification many patent documents are referenced and their citations are indicated. The disclosures of the cited patent documents are incorporated by reference herein in their entirety, and the level of the technical field to which the present invention belongs and the contents of the present invention are more clearly described.

The present inventors have tried to develop a novel material having excellent wrinkle stability, hair loss prevention or hair growth effect, anti-obesity effect and anti-inflammatory effect and high skin stability. As a result, the present invention was completed by confirming that preparation of a composition containing alpha-pinene as an active ingredient can provide a composition for improving skin condition, anti-inflammatory and anti-obesity having excellent efficacy and safety.

Accordingly, it is an object of the present invention to provide a composition for improving skin conditions.

Another object of the present invention to provide a composition for inhibiting inflammation.

Another object of the present invention to provide an anti-obesity composition.

Other objects and advantages of the present invention will become apparent from the following detailed description, claims and drawings.

According to one aspect of the present invention, the present invention provides a composition for improving skin conditions including alpha-pinene as an active ingredient.

According to another aspect of the present invention, the present invention provides an anti-inflammatory composition comprising alpha-pinene as an active ingredient.

According to another aspect of the present invention, the present invention provides an anti-obesity composition comprising alpha-pinene as an active ingredient.

The present inventors have tried to develop a novel single substance for a naturally derived compound having excellent anti-wrinkle effect, hair loss prevention or hair growth effect, anti-inflammatory effect and anti-obesity effect and high stability without skin side effects. As a result, it was confirmed that the preparation of the composition containing alpha-pinene as an active ingredient can provide a composition for improving skin condition, anti-inflammatory and anti-obesity having excellent efficacy and safety.

Alpha-pinene used as an active ingredient in the composition of the present invention is a terpene-based compound of (1R, 5R)-(+)-alpha-pinene and (1S, 5S)-(-)-alpha-pinene. It has two isomeric structures. Alpha-pinene is a fragrant essential oil component and is known as a major component of tee-tree oil. The representative plant where alphapinene exists is Pinus densiflora ), Artemisia vulgaris), chrysanthemum (Chrysanthemum coronarium L.) or pepper (Piper nigrum ). Alpha-pinene is known as an antimicrobial, antifungal, sedative, antistress and memory enhancing effect. IUPAC name is (1R, 5R) -2,6,6-trimethyl bicyclo [3.1.1] hept-2-ene ((1R, 5R) -2,6,6-trimethylbicyclo for (+)-alpha-pinene [3.1.1] hept-2-ene), and for (-)-alpha-pinene, (1S, 5S) -2,6,6-trimethyl bicyclo [3.1.1] hept-2-ene ((1S , 5S) -2,6,6-trimethylbicyclo [3.1.1] hept-2-ene) and have the structures of Formulas 1 and 2, respectively.

Formula 1

Formula 2

Alpha-pinene used as an active ingredient in the composition of the present invention is a natural source (pine) Pinus densiflora , Artemisia vulgaris), chrysanthemum (Chrysanthemum Coronarium L. ) can be extracted using steam distillation, compression or solvent extraction, which is a common essential oil extraction method. Specifically, the alpha-pinene can be obtained using various extraction methods known in the art, and preferably, (a) water, (b) anhydrous or hydrous lower alcohol (methanol) having 1 to 4 carbon atoms. , Ethanol, propanol, butanol, etc.), (c) the mixed solvent of the lower alcohol and water, (d) acetone, (e) ethyl acetate, (f) chloroform or (g) 1,3-butylene glycol It can be obtained as a solvent. More preferably, extraction is carried out using an aqueous methanol and ethanol solution, and most preferably, extraction is performed using an ethanol aqueous solution.

On the other hand, it will be apparent to those skilled in the art that the alpha-pinene of the present invention can be obtained in addition to the above-described extraction solvents, and extracts having substantially the same effect using other extraction solvents.

In addition, the extract of the present invention includes not only the extract by the above-described extraction solvent, but also the extract that has undergone a conventional purification process. Obtained by various additional purification methods, such as, for example, separation using ultrafiltration membranes having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity). The fraction is also included in the extract of the present invention.

The alpha-pinene of the present invention may be prepared in powder form by additional processes such as distillation under reduced pressure and freeze drying or spray drying.

According to a preferred embodiment of the present invention, the skin condition improvement refers to a composition, characterized in that wrinkle improvement, hair growth promotion or hair loss prevention.

The composition for improving skin conditions of the present invention has a wrinkle improvement use. The composition of the present invention exhibits excellent anti-wrinkle effect through molecular mechanisms such as inhibition of collagenase activity and promotion of collagen synthesis while having low cytotoxicity, which is clearly described in the following examples. . Wrinkle improvement, which is the use of the composition of the present invention, is understood to include conventional skin protection applications (prevention of wrinkles, removal of wrinkles, inhibition of skin aging, etc.).

In addition, the composition for improving skin of the present invention works very effectively in promoting hair growth or preventing hair loss. As used herein, the term “anti-hair loss” or “promoting hair growth” is used in the same sense, which has the same meaning as another term wool or hair growth promotion used in the art.

The composition of the present invention includes alpha-pinene as an active ingredient and has an effect of inhibiting an immune related response associated with inflammation. Specifically, alpha-pinene, an active ingredient, inhibits interleukin-2 expression by reducing the activity of the interleukin-2 (IL-2) promoter, which has been reported to play an important role in the production of pro-inflammatory cytokines. It has an immunomodulatory function that effectively inhibits T cell-mediated inflammatory responses.

Therefore, the anti-inflammatory composition of the present invention can be applied to various diseases, diseases or abnormal conditions that can be prevented or treated by inhibiting an immune response. Inflammation-related diseases that can be prevented or treated by the compositions of the present invention include, for example, bullous scutaneous swelling, scar stool swelling, disc lupus, lupus erythematosus, psoriasis, systemic lupus erythematosus, lupus erythematosus, allergy And atopy, but is not limited thereto. The anti-inflammatory composition of the present invention is preferably used for the prevention or treatment of atopy.

In addition, alpha-pinene, an active ingredient of the composition of the present invention, has an excellent anti-obesity effect.

Alpha-pinene of the formulas (1) and (2) of the present invention exhibits antiwrinkle effect by promoting collagen synthesis and / or inhibiting collagenase activity in derivatives obtained by addition or substitution reaction of substituents commonly practiced in the art. It is clear to those skilled in the art, in view of the state of the art, to include derivatives that exhibit hair growth promoting or anti-hair loss, anti-inflammatory and anti-obesity effects. More specifically, the alpha-pinene used as an active ingredient in the present invention, as well as the compounds of the formulas (1) and (2), as a nucleus (nucleus) of the structure of the formulas (1) and (2) various substituents and substituents known in the art Derivatives of formulas (I) and (II) obtained through the coupling reaction are also included in the scope of the present invention. For example, even when a hydroxyl group, a halo group, a nitro group, or an alkyl group having 1 to 3 carbon atoms is bonded to Formulas 1 and 2, the same or similar effect as that of Alpha-pinene of Formulas 1 and 2 is determined, and such a substituted derivative Also included within the scope of the present invention.

In a preferred embodiment of the present invention, the active ingredient of the alpha-pinene is 0.00001 to 15.0% by weight, more preferably 0.0001 to 10% by weight, most preferably 0.0001 to 5% by weight based on the total composition. When the weight of the active ingredient of alpha-pinene is less than 0.00001% by weight, the skin-related efficacy is weak, and when it exceeds 15.0% by weight, the effect of increasing the content is very small and the stability of the formulation is not secured. There is a problem.

According to a preferred embodiment of the present invention, the composition of the present invention is a cosmetic composition.

The components included in the cosmetic composition of the present invention include components conventionally used in cosmetic compositions in addition to alpha-pinene as an active ingredient, and include, for example, conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and perfumes, And carriers. In addition, the cosmetic composition may further include a skin absorption promoting substance to enhance the effect.

The cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like, but are not limited thereto. More specifically, it may be prepared in the form of a nourishing cream, astringent lotion, a flexible lotion, a lotion, an essence, a nourishing gel or a massage cream.

When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, and especially in the case of spray, additionally chlorofluorohydrocarbon, Propellant such as propane / butane or dimethyl ether.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.

When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.

When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.

The composition of the present invention may be prepared as a pharmaceutical composition.

When the composition of the present invention is made into a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers included in the pharmaceutical compositions of the present invention are those commonly used in the preparation, such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, Calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like It doesn't happen. In addition to the above components, the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical compositions of the present invention may be administered orally or parenterally, preferably by parenteral administration, more preferably by topical application by application.

Suitable dosages of the pharmaceutical compositions of the present invention may vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to response of the patient. Can be. The dosage of the pharmaceutical composition of the present invention is in the range of 0.001-100 mg / kg on an adult basis. In addition, in the case of external preparations, it is recommended to continue the application for 1 month to 5 times a day in an amount of 1.0 to 3.0 ml on an adult basis. However, the dosage does not limit the scope of the present invention.

The pharmaceutical compositions of the present invention may be prepared in unit dosage form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporation into a multi-dose container. The formulation may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of extracts, powders, powders, granules, tablets or capsules, and may further comprise dispersants or stabilizers.

In addition, the composition of the present invention may be prepared as a food composition.

When the composition of the present invention is prepared as a food composition, it contains not only alpha-pinene as an active ingredient, but also components commonly added in food production, and include, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavors. Includes the first. Examples of the above carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol. As the flavoring agent, natural flavoring agents (tauumatin, stevia extract (for example rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.

 For example, when the food composition of the present invention is prepared with a drink, in addition to the alpha-pinene of the present invention, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, tofu extract, jujube extract, licorice extract, etc. Can be.

On the other hand, in a specific embodiment of the present invention, the result of the cumulative skin irritation test for alpha-pinene, it was found that alpha-pinene is a natural material harmless to the human body. Therefore, alpha-pinene of the present invention has little toxicity and side effects, so it can be used safely even in long-term use, and in particular, it can be safely applied to cosmetics, pharmaceutical and food compositions as described above.

The features and advantages of the present invention are summarized as follows:

(Iii) The composition of the present invention contains alpha-pinene as an active ingredient.

(Ii) Alpha-pinene, which is an active ingredient, has an excellent skin improvement effect, and the skin improvement includes wrinkle improvement, hair growth promotion or hair loss prevention effect. Alpha-pinene exhibits excellent wrinkle improvement through molecular mechanisms such as inhibition of collagenase activity and promotion of collagen synthesis, and has excellent hair growth promoting or hair loss prevention effect.

(Iii) Alpha-pinene, an active ingredient, has an excellent anti-inflammatory effect, which inhibits immune-related reactions related to inflammation, and free radical scavenging effect.

(Iii) In addition, there is no cytotoxicity and skin side effects, so that it can be safely applied to cosmetics, pharmaceutical and food compositions.

Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, and the scope of the present invention is not limited by these examples in accordance with the gist of the present invention to those skilled in the art. Will be self explanatory.

Example  1: alpha Pinene  Wrinkle improvement effect measurement

The anti-wrinkle effect can usually be measured as collagen biosynthesis and collagenase degradation inhibitory effect and clinical trial in humans. Human normal fibroblasts (Pacific) were inoculated into 6-well microplates containing DMEM medium (2 × 10 ⁵ cells / well) and stored at 37 ° C. in a 5% CO ₂ incubator. Incubated for 24 hours. After 24 hours, the medium was removed from each well, samples were treated by concentration and then incubated again for 24 hours. After 24 hours, cell media were collected to prepare samples.

The amount of collagen synthesized was determined using the collagen measurement kit (Procollagen Type I C-peptide EIA kit (MK101), Takara, Kyoto, Japan), and the amount of procollagen type I C-peptide (Type I C-peptide (PICP)). Was measured. Detailed test method was performed according to the kit instructions of Takara Co., Ltd.

An antibody against collagenase was used as a method for measuring the activity of collagenase, an enzyme that degrades collagen. Porbolol myristate acetate (PMA) (Sigma) was treated with a substance that induces collagenase activity. The entire test was performed according to the vendor's protocol. Type I collagenase assay kit (Amersham Biosciences, RPN2629) was used and absorbance was measured with an ELISA reader (Bio-Tek ELx808 ™ Series Ultra Microplate Reader, UK). The measured standard values were expressed in the form of mean ± standard deviation and tested for significance by t-test using the SPSS / PC + program. The results are shown in Table 1 and FIGS. 1-2 below.

Test Items Alpha-pinene (1 μM) Alpha-pinene (10 μM) Alpha-pinene (50 μM) Collagen Synthesis Growth Rate 15 16 20 Collagenase inhibition rate 13 18 24

As can be seen in Table 1, it can be seen that alpha-pinene inhibits collagenase activity while increasing collagen synthesis. As a result, it can be seen that alpha-pinene has a wrinkle improvement effect. In addition, this increase in collagen synthesis and inhibition of collagenase activity appeared to be dependent on the concentration of alpha-pinene.

Example  2: alpha Pinene  Containing Cosmetic  Wrinkle improvement effect measurement

Wrinkle improvement effect of the cosmetic containing alpha-pinene was measured through clinical trials. Nutritional creams prepared in Preparation Example A (nutrition creams containing alpha-pinene 0.1%, 0.5% and 1%, respectively) and comparative preparation (nutrition creams containing purified water) were used.

Wrinkle improvement effect was evaluated by measuring skin elasticity change. Skin elasticity was measured in 30 healthy women (25 to 35 years old) under the condition that the temperature is maintained at a temperature of 24 to 26 ° C. and a humidity of 38 to 40%. Each subject's face was used twice a day for 3 months, and then measured using Cutometer SEM 474 (Courage + Khazaka, Cologne, Germany). The relative value was compared by setting 5 as. The test results are shown in Table 2 below.

Test Items Preparation Example A (Alpha-pinene 0.1% cream) Preparation A (alpha-pinene 0.5% cream) Preparation Example A (Alpha-pinene 1% cream) Comparative Preparation Example (alpha-pinene 0% cream) Skin elasticity 2.53 2.61 2.79 2.41

As can be seen in Table 2, Preparation Example A of the present invention was much better wrinkle improvement effect than the comparative preparation, skin elasticity was also improved as the concentration of alpha-pinene increased.

Preparation Example A Preparation of Cream Containing Alpha-Pinene Extract

The composition of the nourishing cream containing alpha-pinene is shown in Table 3 below. The aqueous phase purified water, triethanol amine and propylene glycol were heated and dissolved at 70 占 폚, and the oily fatty acid, oil component, emulsifier, and preservative were heated to 70 占 폚 to dissolve the solution. After emulsification was completed the solution was cooled to 45 ° C., alpha-pinene and flavor were added and dispersed and then cooled to 30 ° C.

Ingredients and Contents of Nutritional Cream Containing Alpha-pinene ingredient Content (% by weight) Alpha-pinene 0.1, 0.5 or 1.00 Jojoba oil 5.0 Floating paraffin 7.0 Cetylaryl alcohol 2.0 Polyglyceryl-3 Methyl Glucose Disteare 2.0 Glyceryl Stearate 0.5 Squalane 3.0 Propylene glycol 4.0 glycerin 5.0 Triethanol amine 0.3 Carboxy Vinyl Polymer 0.3 Tocopheryl acetate 0.2 Preservative, incense a very small amount Purified water Remaining amount Sum 100

Example  3: alpha- Pinene  Safety confirmation experiment on human skin

In order to confirm that alpha-pinene extract is safe for human skin, skin safety verification experiment was performed. To this end, a cumulative skin irritation test was performed.

Formulations of 1%, 2%, and 5% alpha-pinene, respectively, based on squalene were prepared, and a total of nine 24-hour cumulative patches were applied to the upper forearm every other day for 30 healthy adults. It was then determined whether alpha-pinene irritated the skin. The patching method used a fin chamber (Finn chamber, Epitest Ltd, Finland). 15 µl of each of the external skin preparations was added dropwise to the chamber, followed by patching. The degree of response to the skin each time was scored using Equation 1 below, and the results are shown in Table 4 below.

Average responsiveness = [{(response x responsiveness) / (total number of subjects x highest score (4 points))} x 100] ÷ number of tests (9)

In the reactivity, ± gives 1 point, + gives 2 points, and ++ gives 4 points, which are judged as safe compositions when the average reactivity is less than 3.

Test substance Number of subjects with response Average responsiveness 1 week 2 weeks 3 weeks Primary Secondary 3rd 4th 5th 6th 7th 8th 9th ± + + + ± + + + ± + + + ± + + + ± + + + ± + + + ± + + + ± + + + ± + + + Control group (squalene) One - -  0 - - --- --- --- --- --- --- --- 0.09 Alpha-Pinene (1%) [Test Group 1] One - -  0 - - --- --- --- --- --- --- --- 0.09 Alpha-pinene (2%) [Test group 2] 2 - -  0 - - --- --- --- --- --- --- --- 0.18 Alpha-pinene (5%) [Test group 3] 3--  0 - - --- --- --- --- --- --- --- 0.27

In Table 4, the test groups 1, 2, and 3 all had ±, +, and ++ for 1, 2, and 3, respectively, and the average reactivity was 0.09, 0.18, and 0.27, respectively. Therefore, since the average reactivity was less than 3, alpha-pinene was determined to be a safe substance for human skin that does not exhibit a distinct cumulative stimulus pattern.

Example  4: anti-inflammatory efficacy evaluation

In order to examine the anti-inflammatory effect, IL-2 (Interleukin-2) activity inhibitory activity was performed according to a conventional method in human Jurkat T cells (Korea Cell Line Bank). Interleukin-2 luciferase experiments are described in J. Ethnopharmacol . 96 (1-2): 211-219 (2005).

sample IL-2 luciferase activity (%) PHA (1 μg / ml) 100 PHA (1 μg / ml) + alpha-pinene (1 ppm) 89 PHA (1 μg / ml) + alpha-pinene (10 ppm) 82 PHA (1 μg / ml) + alpha-pinene (50 ppm) 71

As shown in Table 5, it can be seen that alpha-pinene effectively inhibits the activity of interleukin-2 increased by PHA (phytohemagglutinin, Sigma). It can be seen that it can exhibit the inhibitory efficacy.

Example  5: Anti-obesity  effect

Obesity inhibition test was generally carried out by the following method using a well-known animal. The results are shown in Table 6 below.

The method for measuring obesity inhibitory activity is as follows:

Crj: 7 week old ICR male mice (Higgs River, Japan) were pre-cultured for 1 week and used in experiments with 7 groups of 1 animals. Animals are kept in a constant temperature room set at a temperature of 23 ± 1 ° C, a humidity of 55 ± 5% and an illumination time of 12 hours / day, using Rabo MR (manufactured by Nippon Agricultural Co., Ltd.) for feeding, and freely ingesting water. It was made. Alpha-pinene was prepared in liposome formulation (dissolved in 5% lecithin) to 0.1% and 1%. Each sample solution was adjusted to a concentration of 0.1 ml per 10 g of the mouse to doses of 1.5 g / kg and 1 g / kg. In addition, the control group was a 5% lecithin emulsion. Mice were fasted from the day before administration and were forcibly administered once the next day. The test period was 2 weeks and body weight and general symptoms were measured and observed.

sample Days Weight (g) No treatment group Alpha-pinene (0.1%) Alpha-pinene (1%) Alpha-pinene liposome formulation 5 30.2 31.1 29.8 10 36.8 36.1 34.5 15 43.5 41.5 39.7

As shown in Table 6, alpha-pinene showed an anti-obesity effect, the higher the concentration was observed to increase its efficacy.

Example  6: hair loss prevention and Hair growth effect

In order to investigate the hair loss prevention and hair growth effects of alpha-pinene according to the present invention, the following experiment was performed.

1. Preparation of Hair Regrowth Composition

The hair-repellent composition containing alpha-pinene was prepared as the component content of Table 7 to prepare a hydrogel base. Test groups 1 and 2 are hair repellent compositions each comprising alpha-pinene.

ingredient content(%) Test group 1 Test group 2 Alpha-pinene 0.1 1.0 Preservative (Gramben) 0.8 0.1 Thickener (Xanthan-Gum) 0.3 0.1 Total weight 100 100

2. Hair loss prevention and hair growth effect measurement

From 40's to 60's, 40 patients were divided into 4 groups, including alopecia baldness alopecia, typical male alopecia, and acute alopecia areata. The hair restorer prepared in 1 was applied to the bald area of the alopecia patient twice a day for 3 months each for 3 months. Hair loss and hair growth were observed on a monthly basis. A commercial moxidyl (Hanmi Pharm) was used as a comparison group, and only 50% ethanol was applied as a control group.

The criteria are as follows:

4 : High effect = newborn hair is visible

3 : moderate effect = visible newborn hair (down)

2 : slightly effective = the number of hair loss is reduced

1 : no effect = no change at all

The results are shown in Table 8.

- Control Comparison Experimental group 1 Experiment group 2 Efficacy / effect One 4 3 4

As shown in Table 8 above, hair loss including bristles including new hairs began to appear in the alopecia patients with the alopecia containing alpha-pinene of the present invention from one month or two months of treatment and at least 80% at six months of treatment. The hair growth effect appeared in the patient. In addition, it was observed that new hair grew continuously and no hair loss was found.

Examples of preparations for the compositions of the present invention are illustrated below.

Formulation example  One  : Cosmetics  Formulation

1. Flexible cosmetics (content: wt%)

Alpha-Pinene 0.01

Glycerin 3.0

Butylene Glycol 2.0

Propylene Glycol 2.0

Carboxy Vinyl Polymer 0.1

Ethanol 10.0

Triethanolamine 0.1

Preservatives, trace pigments, trace fragrances and traces

Total 100.0

2. Nutritional Cosmetics (Content: Weight%)

Alpha-Pinene 0.01

Beeswax 4.0

Polysorbate 60 1.5

Sorbitan Sesquioleate 0.5

Liquid Paraffin 5.0

Squalane 5.0

Caprylic / Capric Triglycerides 5.0

Glycerin 3.0

Butylene Glycol 3.0

Propylene Glycol 3.0

Carboxy Vinyl Polymer 0.1

Triethanolamine 0.2

Preservatives, trace pigments, trace fragrances and traces

Total 100.0

3. Nutrition Cream (Content: Weight%)

Alpha-Pinene 0.01

Beeswax 10.0

Polysorbate 60 1.5

Sorbitan Sesquioleate 0.5

Liquid Paraffin 10.0

Squalane 5.0

Caprylic / Capric Triglycerides 5.0

Glycerin 5.0

Butylene Glycol 3.0

Propylene Glycol 3.0

Triethanolamine 0.2

Preservatives, trace pigments, trace fragrances and traces

Total 100.0

4. Massage cream (content: wt%)

Alpha-Pinene 0.01

Beeswax 10.0

Polysorbate 60 1.5

Sorbitan Sesquioleate 0.8

Liquid Paraffin 40.0

Squalane 5.0

Caprylic / Capric Triglycerides 4.0

Glycerin 5.0

Butylene Glycol 3.0

Propylene Glycol 3.0

Triethanolamine 0.2

Preservatives, trace pigments, trace fragrances and traces

Total 100.0

5. Pack (Content: Weight%)

Alpha-Pinene 0.01

Polyvinyl Alcohol 13.0

Sodium Carboxymethylcellulose 0.2

Allantoin 0.1

Ethanol 5.0

Nonylphenyl Ether 0.3

Preservatives, trace pigments, trace fragrances and traces

Total 100.0

Formulation example  2  : Pharmaceutical Formulations

1. Preparation of powder

Alpha-Pinene 2g

1g lactose

The above ingredients were mixed and filled in airtight cloth to prepare a powder.

2. Preparation of Tablets

Alpha-pinene 100 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

3. Preparation of Capsule

Alpha-pinene 100 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.

As described in detail above, the present invention provides a composition comprising alpha-pinene as an active ingredient. Alpha-pinene, an active ingredient used in the composition of the present invention, has an excellent skin improvement effect, and the skin improvement includes wrinkle improvement, hair growth promotion or hair loss prevention effect. Alpha-pinene exhibits excellent wrinkle improvement through molecular mechanisms such as inhibition of collagenase activity and promotion of collagen synthesis, and has excellent hair growth promoting or hair loss prevention effect. In addition, alpha-pinene has an excellent anti-inflammatory effect of inhibiting the immune-related response associated with inflammation, free radical elimination effect and an excellent antioxidant effect and obesity inhibitory effect. And there is no cytotoxicity and skin side effects can be safely applied to cosmetics, pharmaceutical and food compositions.

Having described the specific part of the present invention in detail, it is apparent to those skilled in the art that such a specific technology is only a preferred embodiment, and the scope of the present invention is not limited thereto. Therefore, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

Claims (9)

A composition for improving skin wrinkles comprising alpha-pinene as an active ingredient. delete delete delete The composition of claim 1, wherein the alpha-pinene is included in an amount of 0.0001-10.0% by weight based on the total weight of the composition. The composition of claim 1, wherein the composition is a cosmetic composition. 7. The group of claim 6 wherein the composition consists of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray A composition characterized by having a formulation selected from. The composition of claim 1, wherein the composition is a pharmaceutical composition. The composition of claim 1 wherein the composition is a food composition.

Images